1. Home
  2. BGSF vs LUNG Comparison

BGSF vs LUNG Comparison

Compare BGSF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$6.07

Market Cap

63.4M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.36

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
LUNG
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
72.2M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
BGSF
LUNG
Price
$6.07
$1.36
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$9.00
$5.38
AVG Volume (30 Days)
24.1K
680.2K
Earning Date
03-11-2026
03-04-2026
Dividend Yield
32.36%
N/A
EPS Growth
67.37
7.64
EPS
N/A
N/A
Revenue
$272,499,000.00
$90,497,000.00
Revenue This Year
$4.67
$6.20
Revenue Next Year
N/A
$21.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$2.91
$1.31
52 Week High
$8.20
$7.97

Technical Indicators

Market Signals
Indicator
BGSF
LUNG
Relative Strength Index (RSI) 54.39 37.62
Support Level $5.93 N/A
Resistance Level $6.38 $2.01
Average True Range (ATR) 0.26 0.17
MACD -0.03 -0.03
Stochastic Oscillator 39.77 5.29

Price Performance

Historical Comparison
BGSF
LUNG

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: